MedPath

To know the efficacy of topical carboxymethylcellulose (0.5%), cyclosporine (0.03%) & chloroquine (0.03% ) in cases of dry eye disease

Phase 2
Conditions
Health Condition 1: H048- Other disorders of lacrimal system
Registration Number
CTRI/2023/07/054823
Lead Sponsor
IMS BH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Cases of moderate to severe dry eye disease with best corrected visual acuity of more than or equal to 660 attending the outpatient department of RIO, IMS, BHU.

Cases giving written consent to participate in the study

Exclusion Criteria

sensitivity to eyedrops

ocular infection, ocular injury or trauma or past ocular surgery.

uncontrolled systemic disease

contact lens wearer.

chronic alcoholics, pregnant or lactating women. already received treatment for dry eye disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
•Slit lamp biomicroscopy <br/ ><br>•Schirmer’s test using 41 no Whatmann filter paper strips <br/ ><br>•Tear film break up time using fluorescein staininG <br/ ><br>•Ocular Surface disease index (OSDI) <br/ ><br>•Fluorescein stain score <br/ ><br>Timepoint: <br/ ><br>DAY 0 <br/ ><br>WEEK 1 <br/ ><br>WEEK 4 <br/ ><br>WEEK 8 <br/ ><br>WEEK 12 <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
VISUAL ACUITY <br/ ><br>BEST CORRECTED VISUAL ACUITY <br/ ><br>SLIT LAMP BIOMICROSCOPYTimepoint: DAY 0 <br/ ><br>WEEK 1 <br/ ><br>WEEK 4 <br/ ><br>WEEK 8 <br/ ><br>WEEK 12
© Copyright 2025. All Rights Reserved by MedPath